Tesla Model 3 Review: A Facelifted Electric Marvel

By Editorial Team -
The Tesla Model 3, an electric sedan, has been refreshed with a new look and some exciting features. Let’s dive into the details.


Overview: There are two variants of the Model 3: the base model with 245 bhp, a 57 kWh battery, and rear-wheel drive, and the Long Range model with 351 bhp, a 75 kWh battery, and all-wheel drive. The facelift brings subtle changes to the exterior, making it sleeker and more aerodynamic. The headlights are sharper, and the overall effect pays homage to Tesla’s original Roadster from 2008. The range has improved to 318 miles for the standard model and an impressive 390 miles for the Long Range version.

Interior and Material Quality: Inside, the Model 3 maintains its minimalist design. Material quality has seen an uptick, although the wisdom of white seats in a family car remains debatable. The recent price drops make the Model 3 even more appealing, with prices starting at £39,990 for the base model and £49,990 for the Long Range variant. Tesla claims no plans for another Performance iteration, but we know how Tesla surprises us.

Driving Experience: The Model 3’s performance remains impressive. It accelerates from 0 to 62 mph in 6.1 seconds (base) and 4.4 seconds (Long Range). Top speed is capped at 125 mph. The extra range is a welcome addition, especially considering that it was already ahead of most rivals.

Positive Reviews:

In summary, the Tesla Model 3 continues to be a disruptor in the electric car market, setting the benchmark for others to follow. With improved range, sleek design, and cutting-edge tech, it’s a compelling choice for eco-conscious drivers.

References:

  1. Top Gear: “Tesla Model 3 Review.” Available online: Top Gear Tesla Model 3 Review
  2. Car and Driver: “2021 Tesla Model 3 Review.” Available online: Car and Driver Tesla Model 3 Review

Comments

Post a Comment

Pages

Popular posts from this blog

Top 10 Pharmaceutical Companies by Revenue in 2025

By Editorial Team -
Image
With only one of the biopharma industry’s top 20 revenue companies seeing a year-over-year decline in sales, 2024 was a remarkable year of revenue growth for the industry. Compare that to 2023, when eight of the top 20 drugmakers experienced revenue declines. Six of the top 20 drugmakers had double-digit increases in 2024, compared to just two in 2023. Five others saw a revenue bump of between 7% and 9%, compared to two reaching those figures in 2023. For the second year in a row, Eli Lilly (32%) and Novo Nordisk (26%) posted Big Pharma's largest year-over-year sales bumps, though their positions were flipped from 2023 when Novo (31%) topped Lilly (20%). Expect the same form in 2025 as Lilly—boosted by sales of its diabetes and obesity drugs Moujaro and Zepbound— projects  its sales to fall between $58 billion and $61 billion. At the midpoint of the projection, it would be a 32% increase, matching the sales boom it saw last year. Meanwhile, Novo—which also has been powered by sale...
Read more

Top 10 Drugs by Worldwide Sales in 2024

By Editorial Team -
Image
It's been several years since COVID-19 vaccines from Pfizer and Moderna jumped to the top of the pharma industry's sales charts, displacing longtime stalwarts with unprecedented sales. But, as 2023 featured major patent expirations, the rise of weight loss drugs and other new dynamics, the year’s ranking of the top 10 drugs by global sales featured its fair share of surprises. Merck’s oncology king Keytruda rose to the top last year, adding yet another feather in its cap. With more than 30 indications across various cancer types and stages, the PD-L1 inhibitor shows no signs of stopping. With $25 billion in global sales, the drug accounted for about 40% of Merck’s total revenue last year. Keytruda's sales are expected to reach $30 billion this year. Keytruda had previously fallen right behind AbbVie's Humira, which held the title of the world’s bestselling drug for nine years in a row until Pfizer and BioNTech’s Comirnaty knocked AbbVie’s Humira off its perch in 2021. N...
Read more

7 Best Crypto Exchanges Malaysia 2025

By Editorial Team -
Image
If you're looking for the best cryptocurrency exchanges in Malaysia in 2025, it's important to choose platforms that are secure and fully compliant with local regulations. In Malaysia, Digital Asset Exchanges (DAX) are regulated and licensed by the Securities Commission Malaysia (SC), which ensures they meet strict standards for investor protection and legal compliance. Luno, Binance, Sinegy, Tokenize Exchange, MX Global, Hata and Torum are popular choices. The best cryptocurrency exchanges work similarly to the best stock trading apps, offering competitive fees and resources on digital marketplaces like mobile or desktop. Crypto enthusiasts can easily buy, sell, and store popular digital currencies like Bitcoin or altcoins like Ethereum. Note that if you don't want to use your exchange's built-in wallet (if applicable), you'll need to set up an external crypto wallet, to store your assets securely. Here are details of cryptocurrency exchanges you can use to buy Bit...
Read more

Top 10 Cancer Drug Companies of 2025

By Editorial Team -
Image
Merck, Roche and Celgene (now part of Bristol-Myers Squibb) have remained prominent players, but the market dynamics have shifted significantly in recent years. This increased competition is fueled by the success of blockbuster drugs like Keytruda (Merck), Tagrisso (AstraZeneca), and Ibrance (Pfizer), as well as the rapid adoption of immunotherapies and targeted treatments ( Verified Market Reports ). Look at 2017. The trio of drugmakers together held a 45.8% share of the market, with longtime cancer leader Roche controlling 26.4% all on its own. In 2024, though, market intelligence firm EvaluatePharma expects to see much more parity. The top three’s share will shrink to 26.2%, with Roche’s dropping all the way down to 11.9%. And the No. 2 through No. 5 companies—BMS, Johnson & Johnson, Pfizer, AstraZeneca and Merck—will boast shares within less than a percentage point of one another. And it won’t just be the heavy hitters clawing for a piece of the pie. That number is set to near...
Read more

5 Top Silver ETFs 2025: What You Need to Know

By Editorial Team -
Image
Along with gold, silver is in high demand as precious metals are highly sought after as safe havens in uncertain economic environments, boosting prices and assets for top silver ETFs like the iShares Silver Trust (SLV). Investors use silver ETFs for various purposes. Other than its safe-haven benefits, some invest for speculative reasons, hoping to profit from potential increases in silver prices or as a hedge against geopolitical turmoil or currency devaluation. Keep reading to learn more about investing in silver and see a list of top ETFs investing in the precious metal.   What Are Silver ETFs?  Silver ETFs are exchange-traded funds that provide exposure to the price of silver, a precious metal. These ETFs are designed to track the performance of silver prices, making it easier for investors to gain exposure to the silver market without physically owning and storing the metal itself. Silver's unique combination of properties, including its electrical conductivity, thermal c...
Read more

Top 10 Pharma Companies by R&D Spend 2024

By Editorial Team -
Image
In 2024, the pharmaceutical industry witnessed significant shifts in research and development (R&D) investments, with companies like Merck & Co. and AstraZeneca making notable strategic decisions that impacted their positions among top R&D spenders. The average cost for major pharmaceutical companies to develop a drug in 2024 rose to $2.23 billion, up from $2.12 billion the previous year. This increase reflects the growing complexity and expense associated with bringing new therapies to market. ​( Fierce Biotech ) These developments illustrate the dynamic nature of R&D investments in the pharmaceutical sector, influenced by strategic partnerships, acquisitions, and the escalating costs of drug development. 1. Merck & Co. R&D SPENDING 2024: $17.9 billion Change from 2023: -41% Total 2024 revenue: $64.2 billion R&D budget as percentage of revenue: 28% Market capitalisation: 198.3 B USD (as of June 2025) Merck & Co.’s R&D spending plummeted from the d...
Read more

Lithium Battery Incidents on US Flights Occur Weekly on Average, FAA Data Show

By Editorial Team -
Incidents triggered by lithium-ion batteries are now, on average, a weekly occurrence on U.S. flights, according to the U.S. Federal Aviation Administration (FAA), with cabin crews expressing concern over the risk. This year, 69 lithium battery incidents involving smoke, fire, or extreme heat have occurred on U.S. flights as of Dec. 16, FAA data show. This equates to more than 1.3 incidents per week. Since 2015, the number of such events has increased by more than 330 percent. Between March 3, 2006, and Nov. 5, 2024, a total of 579 lithium battery incidents were recorded, with the majority of cases coming from passenger carriers. Battery packs and batteries accounted for the bulk of these incidents, with 229 events, followed by e-cigarettes/vape devices with 122, cell phones with 81, laptops with 70, and the rest involving other electronic and medical devices. On Nov. 5, a smoke detector alarm from the lavatory of a United Airlines flight coming from San Francisco went off. “Flight a...
Read more

Did Steve Jobs Refuse Treatment for Pancreatic Cancer?

By Editorial Team -
Image
On October 5, 2011, Steve Jobs died after a battle with a rare pancreatic cancer at age 56. But he may have lived longer if he sought proper medical care in time. When Apple co-founder Steve Jobs was first diagnosed with pancreatic cancer in 2003, his doctors advised him to seek surgery as soon as possible. Instead, he delayed the procedure for nine months and attempted to treat himself with alternative medicine. This fateful decision may have quickened Steve Jobs’ death — when he still could’ve been saved. Steve Jobs died from pancreatic cancer complications on October 5, 2011, just eight years after his initial diagnosis. He was only 56 years old when he died, but his cancer had taken such a toll on his body that he looked gaunt, frail, and much older than his actual age. It was a far cry from the robust, energetic man who had once pioneered the personal computer era.    ...
Read more

12 Best SME Business Loans in Malaysia 2025

By Editorial Team -
Image
Several banks in Malaysia offer business loans tailored for SMEs. Maybank and CIMB are popular choices, offering a variety of loan amounts and competitive interest rates. Other notable options include Public Bank and RHB, while SME Bank and MIDF also provide dedicated financing solutions for small and medium-sized enterprises.   SME or also known as Small and Medium-sized Enterprises are businesses that maintain revenues, assets, or a number of employees below a certain threshold. These business entities are often regarded as the heartbeat of Malaysia’s emerging and developing economies. Apart from providing vast numbers of employment opportunities, SME businesses are generally entrepreneurial in nature, helping to shape innovation. Generally, there are two criteria to be met in order for your business to qualify as an SME -- your annual sales turnover and the number of full time employees in your company. This also implies differently for each economy sector: Manufacturing (S...
Read more

Bitcoin Nasdaq Correlation: The Correlation between the Nasdaq index and Cryptocurrencies 2025

By Editorial Team -
Image
The correlation between the Nasdaq index and cryptocurrencies, particularly Bitcoin, has been a subject of interest and analysis, reflecting the increasing integration of digital assets into the broader financial ecosystem. Here's a detailed look at this relationship: Historical Context and Trends: Increasing Correlation : Over the past few years, there has been a noticeable trend towards a stronger correlation between Bitcoin and the Nasdaq Composite Index, especially with tech-heavy indices like the Nasdaq 100. As of early 2025, this correlation has been observed to be at a high level, with some periods showing a correlation coefficient above 0.9. This suggests that movements in Bitcoin prices often mirror those of the Nasdaq, particularly during bullish market phases for tech stocks. Institutional Influence : The growing involvement of institutional investors in cryptocurrencies has played a significant role in this correlation. Companies like Coinbase, which has a listing on Na...
Read more